A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.
Alacrita's diagnostic consultant reviewed the competitive positioning of the company. Our analysis demonstrated that although the novel platform had superior economics relative to key competitors, its potential lead could be eroded due to the time needed to broaden the test menu. As such, investor returns were lower than targeted and the investment did not proceed.